Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Colonic Neoplasms 1

Interventions

Oxaliplatin 95Fluorouracil 84Capecitabine 75Gemcitabine 72Leucovorin 68Nivolumab 67Bevacizumab 63pembrolizumab 61Magnetic Resonance Spectroscopy 52Specimen Handling 50Irinotecan 50durvalumab 46Radiotherapy 42atezolizumab 40Cisplatin 39Paclitaxel 37Biopsy 37130-nm albumin-bound paclitaxel 34Cetuximab 30Carboplatin 27Albumin-Bound Paclitaxel 26Taxes 24Drug Therapy 20dehydroftorafur 19Radiation 19Ipilimumab 19tislelizumab 18Standard of Care 17Docetaxel 17trifluridine tipiracil drug combination 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × CIMAvax EGF × Gastrointestinal × Clear all
NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
2 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡